ENTA News and Press, Enanta Pharmaceuticals Inc. From 12/03/21

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Enanta Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Enanta Pharmaceuticals (ENTA +14.8%) has recorded the biggest intraday gain since March 2020 after the company issued its Q4 financials for fiscal 2021 on Monday after the close. While revenue slipped ~0.2% YoY to $23.6M missing the consensus, the net loss per share was better than feared ...

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2021 Earnings Conference Call November 22, 2021 04:30 AM ET Company Participants Dr. Jay Luly – President and Chief Executive Officer Jennifer Viera – Investor Relations Paul Mellett – CFO Nathalie Adda – Chief Medical Officer...

Image source: The Motley Fool. Enanta Pharmaceuticals, inc (NASDAQ: ENTA) Q4 2021 Earnings Call Nov 22, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals, inc (ENTA) Q4 2021 Earnings Call Transc...

Enanta Pharma (NASDAQ:ENTA): FQ4 GAAP EPS of -$1.22 beats by $0.06. Revenue of $23.58M (-0.2% Y/Y) misses by $2.76M. Shares +0.38%. Press Release For further details see: Enanta Pharma EPS beats by $0.06, misses on revenue

Presented First Preclinical Data for EDP-235, an Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19; First-in-Human Study Planned for Early 2022 Reported Positive Clinical Data from Two Phase 1b Studies of EDP-514, a Hepatitis B Virus (HBV) Core Inhi...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal fourth quarter and year-ended September 30...

EDP-514 is Safe and Well-Tolerated up to 800 mg Robust Antiviral Activity Demonstrated in Chronic Hepatitis B Virus Patients at All Doses Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs fo...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...